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Nontuberculous mycobacteria 
in gastrostomy fed patients with 
cystic fibrosis
H. Al-momani1, A. Perry2, R. Jones1, S. Bourke3, S. Doe3, J. Perry2, A. Anderson3, T. Forrest3, 
I. Forrest3, M. Griffin3, M. Brodlie1, J. Pearson1 & C. Ward1
Multi-drug resistant Mycobacterium abscessus complex (MABSC) is a form of Nontuberculous 
mycobacteria (NTM) of special, international concern in Cystic Fibrosis (CF). We hypothesised that 
gastric juice and percutaneous endoscopic gastrostomy (PEG) feeding devices might yield MABSC 
isolates. Gastric juice and sputa from sixteen adult PEG fed CF patients and five replaced PEG tubes 
were studied. Bacterial and fungal isolates were cultured. Mycobacterium were identified by rpoB, sodA 
and hsp65 gene sequencing and strain typed using variable number tandem repeat. Bacteria and/or 
fungi grew from all gastric juice, sputa and PEG samples. MABSC were detected in 7 patients. Five had 
MABSC in their sputum. Two had an identical MABSC strain in their sputum and gastric juice and one 
had the same strain isolated from their PEG tube and sputum. Two patients who were sputum sample 
negative had MABSC isolated in their gastric juice or PEG tube. MABSC were therefore identified for the 
first time from a gastric sample in a minority of patients. We conclude that gastric juice and PEG-tubes 
may be a potential source of MABSC isolates in CF patients, and these findings warrant further study.
Non tuberculous mycobacteria (NTM) are important human pathogens responsible for a wide spectrum of soft 
tissue infections, which are recognised to cause disseminated infection in immunocompromised patients. The 
incidence and prevalence of pulmonary NTM infection is increasing worldwide, contributing to concerns that 
NTM infection may become a serious health challenge1.
NTM infection is of special, international concern in people with CF and represents a significant emerging 
threat in patients with CF. Estimates of the prevalence of NTM in the CF population range from 1.3% to 32.7% 
depending on the geographical region and patient population2. To date, the largest CF studies report rates of 
NTM-positive respiratory cultures between 6.6% and 13.7%2.
Of the rapidly growing NTM species, the multidrug resistant Mycobacterium abscessus complex (MABSC) has 
emerged as a major respiratory pathogen particularly in individuals with CF, that is associated with an accelerated 
decline in lung function3. MABSC can also prevent safe lung transplantation, which is one of the few therapeutic 
approaches available in end stage lung disease. It is for this reason that many transplant centres consider active 
MABSC pulmonary disease to be a relative contraindication to lung transplant listing4. Treatment of MABSC is 
challenging, requiring extended therapy with combinations of multiple antibiotics required that may be associ-
ated with adverse effects and is not always successful clinically5.
MABSC can be divided into three subspecies (subsp): Mycobacterium abscessus subsp abscessus, M abscessus 
subsp massiliense, and M abscessus subsp bolletii6. A recent publication demonstrated a potential high rate of 
transmission of MABSC between CF patients despite stringent segregation7. It was postulated that transmission 
could occur indirectly, through fomite contamination or through aerosol generated during physiotherapy and 
spirometry testing8. The study also demonstrated that inferred transmission might occur from patients with per-
sistent smear negative, culture positive sputa. This suggested that only a low level of inoculum might be needed 
for infection, contributing to debate regarding the need for rigorous preventative measures8.
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We have recently described findings of a gastric juice reservoir of organisms relevant to CF lung pathophysi-
ology in patients fed by percutaneous endoscopic gastrostomy (PEG) tubes, which also confirmed a widespread 
presence of extra oesophageal reflux (EOR) symptoms and potential for micro-aspiration in patients with CF9,10.
This is consistent with the established diagnostic role for gastric aspirate culture in pulmonary tuberculosis11,12 
and the finding that repeated gastric lavage has better sensitivity for microbiological diagnosis of childhood pul-
monary tuberculosis compared with bronchoalveolar lavage11,13. The potential gastric juice culture of MABSC in 
people with CF has not been established to our knowledge however.
We hypothesised that gastric juice and PEG tubes from people with CF might yield NTM isolates, and in par-
ticularly MABSC. The aim of this cross-sectional study was therefore to provide a description of the NTM isolates 
of sputum, gastric juice and PEG tubes from adult CF patients.
Methods
Ethical approval. Research Approval was obtained from Newcastle and North Tyneside Research Ethics 
Committee to perform research on samples collected as part of the Hepatopancreatobiliary groups biobank based 
in Newcastle University. All study participants provided written informed consent prior to initiation of the study. 
All methods were carried out in accordance with relevant guidelines and regulations.
Patients and sample. CF patients receiving PEG feeding represented an important opportunity to directly 
sample gastric juice, with less potential for contamination with oropharnygeal commensals. From the 270 CF 
patients attending the regional CF Centre, a potential 16 PEG-tube fed patients were available for study (Table 1).
Following overnight fasting gastric juice and sputum samples from those PEG-tube fed CF patients (CF 1–16). 
PEG tubes which became available due to renewal or removal as part of routine PEG management were collected 
form 5 patients (CF 4–6 and CF 14–15). All the potentially available patients with PEG tubes in the region were 
therefore included in this study. No PEG fed CF patients were excluded or positively selected for in the study.
Symptoms of extraoesophageal reflux. Patients with CF had symptoms of extraoesophageal reflux 
(EOR) assessed using the Reflux Symptoms Index (RSI) score; with a score of less than 13 classed as not EOR 
symptomatic14. The reflux symptom index is a patient reported outcome measure designed to assess laryngeal 
symptoms secondary to reflux, including cough.
Sample processing. Gastric juice pH was measured using pH strips and sputum samples were homogenised 
with equal amounts of Dithiothreitol for 1 to 3 minutes. The inner and outer part of the PEG tube were divided 
into small pieces and vigorously washed with 3 ml saline, yielding a PEG conditioned saline (PEG-s).
Microbiological culture conditions. Gastric juice, sputum samples and PEG-s underwent microbiologi-
cal culture performed in accordance with national accredited methods. 10 μ l of homogenised sputum, gastric 
juice and PEG-conditioned saline were plated for bacterial and fungal cultures. The following media were used: 
Patient Genetics Age RSI score PPI yes/no Gastric Juice pH FEV1 (% pred) BMI IV days/year Long-term antibiotic
CF-1 F508del/F508del 26 17 Yes 6 2.0 L (52%) 19.9 22 Azith Inh Coli Inh Tob
CF-2 F508del/F508del 27 20 Yes 2 1.7 L (42%) 23.2 70 Azith Fluclox Inh coli
CF-3 F508del/F508del 20 25 Ranitidine 3 0.8 L (26%) 19.5 28 Azith Fluclox Inh Coli
CF-4 F508del/F508del 24 36 Yes 6 0.76 L (28%) 19 154 Azith Inh Coli
CF-5 F508del/F508del 31 16 Yes 6 0.5 L (12%) 19.1 70 Azith Inh Coli
CF-6 F508del/R117H 22 16 Yes 3 2.7 L (66%) 16.4 14 Fluclox
CF-7 I507del/Arg560Lys 18 13 Yes 2 3.5 L (88%) 19.4 37 Fluclox Inh Coli Inh Tob
CF-8 F508del/R117H 30 14 Yes 6 1.55 L (46%) 17.8 56 Fluclox Inh Coli
CF-9 F508del/F508del 25 17 Yes 2 1.7 L (38%) 15.9 98 Azith Fluclox Inh Tob
CF-10 F508del/G542X 32 NA No 2 1.15 L (36%) 19.4 112 Azith Inh Coli
CF-11 F508del/F508del 30 19 Yes 6 1.2 L (29%) 19.8 115 Azith Fluclox Inh Coli
CF-1 F508del/G542X 24 15 Yes 2 1.65 (36%) 15.24 197 Azith Inh Coli Inh Tob
CF-13 F508del/rg851Ter 23 22 Yes 6 2.3 (59%) 20.2 56 Azith
CF-14 F508del/F508del 25 24 Yes 4 0.85 L (29%) 17.3 84 Azith Inh Colistin Fluclox
CF-15 F508del/Arg851Ter 25 8 Yes 3 2.1 L (54%) 20.1 56 Doxycycline, Azith
CF-16 F508del/Ile507del 36 NA Yes 4 0.72 L (17%) 21.9 112 Inh Colistin
Table 1.  Demographic data for CF patients. Key: Azith = oral azithromycin long-term. Fluclox = oral 
flucloxacillin long-term. Inh Coli = inhaled colistin (nebulised or inhaler). Inh Tob = inhaled tobramycin 
(nebulised or inhaler). RSI score = Reflux symptom index score, < 13 normal. NA = not available, IV days/
year = Number of days per year that CF patient treated with intravenous antibiotics.
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Columbia blood agar supplemented with 5% horse blood, chocolate agar supplemented with 70 mg/L bacitracin, 
Burkholderia selective agar (for CF sputa and gastric juice, CEP bioMérieux UK), cysteine lactose electrolyte 
deficient agar (CLED) and fastidious anaerobic agar (FAA). Plates were incubated according to a standard proto-
col, CEP cultures were incubated for 10 days at 30 °C for isolation of Burkholderia cepacia complex and rapidly 
growing mycobacterium.
Plates were examined daily for evidence of microbial growth and assessment of the number of distinct colo-
nial variants was recorded. All morphological variants were sub-cultured and used for identification and stored 
at − 20 °C in 10% glycerol skimmed milk. Isolates were identified by matrix assisted laser desorption ionisation 
time-of-flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, UK) and where necessary, appropriate API 
kits (bioMérieux, UK)15. Mycobacterium was identified by rpoB, sodA and hsp65 gene sequencing and strain 
typed using variable number tandem repeat (VNTR), Colindale, UK7.
Statistical analysis. Univariate analysis was used to compare differences in demographic and clinical vari-
ables between CF patients with and without MABSC isolates. Comparisons were unpaired, and all tests of signif-
icance were two-tailed.
All data analyses were performed using SPSS for Windows, version 22; p-values < 0.05 were considered to be 
statistically significant.
Results
CF Patients. This patient cohort had moderate to severe CF lung disease, which was in keeping with this 
PEG fed population (median FEV1, 1.6 L (37% predicted) range 0.5–2.7 L (17–88%), along with as is the norm in 
patients with CF, long term antibiotic exposure and use of acid suppression medication (Table 1).
Sputa and gastric juice microbiological results. Of the 16 patients investigated, the most frequent 
microorganisms detected were Streptococcus spp, MABSC, P. aeruginosa and Candida spp in both sputum and 
gastric juice samples. The exceptions were Aspergillus and Rothia spp which were more common in sputum sam-
ples while lactobacillus spp was more common in gastric juice samples (See e-Tables 1 and 2 in the online data 
supplement for CF gastric juice and CF sputum samples culture results). The most frequently isolated bacterial 
taxa from the gastric juices were Lactobacillus (6/16), P. aeruginosa (4/16), Streptococcus spp (3/16), and MABSC 
(3/16). Candida species were isolated from 14 gastric juice samples (Fig. 1).
Identification of the bacteria isolated from 16 sputum samples revealed 13 different bacterial genera with 
Streptococcus spp (13/16), P. aeruginosa (7/16), MABSC (4/15), Achromobacter spp (3/16) and Rothia (11/16) the 
most frequently isolated from sputum samples. Candida species only were isolated in 4 sputum samples (Fig. 2).
Microbiological findings in PEG tube conditioned saline (PEG-s). PEG tubes were removed from 
5 patients (CF4-6 and CF-14-15) as part of their routine management, not due to clinical suspicion regarding 
potential microbiological infection. Bacterial and fungal species were isolated from all PEG tubes. The bacterial 
species isolated included MABSC, P. aeruginosa, lactobacillus, Enterococcus and Staphylococcus sp, isolated in 2 
patients. Candida species were isolated in 4 patients (Fig. 3).
MABSC culture results. MABSC were detected in 7 out of 16 CF patient (43%), 5 patients had MABSC in 
their sputum, 3 patient with Mycobacterium massiliense (CF-3, CF-9, CF-13) and 2 with Mycobacterium abscessus 
sub sp abscessus (CF-6 and CF-4). Among the 5 patients with sputum isolates, 2 had the identical strain of MABSC 
confirmed by VNTR in their gastric juice (M. massiliense in CF-3 and CF-13) and one patient had the same strain 
isolated from their PEG tube (M. abscessus sub sp abscessus (CF-4).
Figure 1. Microbiology culture results for CF gastric juice samples. 
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2 patients who were sputum sample negative for MABSC (CF-1 and CF-14) had either M. massiliense in their 
gastric juice (CF-1) or M. abscessus sub sp abscessus and M. bolletii isolated from their PEG tube (CF-14). MABSC 
were therefore isolated for the first time from a non-respiratory lung, gastric site, in these patients (Table 2).
Longitudinal sputum MABSC culture results in CF patients where MABSC was first isolated 
from a non-respiratory, gastric site. MABSC was first isolated from a non-respiratory, gastric site in CF 
patients 1 and 14. Negative sputum samples were obtained through the clinical surveillance samples obtained at 
clinic visits prior to isolation of NTM from the gastric compartment.
CF 1. M. massiliense was isolated from gastric juice on 23-1-15. Eighteen sputum samples, over 20 months, 
were examined for NTM prior to this (dates: 22-5-13 to 23-1-15). Following the positive gastric sample, ten sputa 
were negative for NTM after this (23-1-15 to 2-3-16). A transient isolation of sputum M. abscessus subspecies 
abscessus occurred on 2-3-16. Seven subsequent sputa were negative for NTM (21-3-16 to 2-12-16).
CF 14. The positive gastric sample (percutaneous endoscopic gastrostomy tube) was identified on 15-7-14, 
with isolates of M. abscessus subspecies abscessus sequence type 26 and M. bolletti. Prior to this five lung samples 
were examined for NTM (9-8-13 to 26-6-14; two sputa and three cough swabs). Seventeen subsequent sputum 
samples were examined and were negative for NTM (dates 13-8-14 to 22-10-16).
The longitudinal culture data were therefore consistent with the possibility that a gastric sample can represent 
the first isolation of NTM in people with CF independent of sputum samples.
Symptoms of extraoesophageal reflux in CF patients. Symptom scores for extraoesophageal reflux 
were available in 14 of the 16 patients with CF (Table 1). 13 patients were EOR symptomatic, despite the use of PPI 
Figure 2. Microbiology culture results for CF sputum samples. 
Figure 3. Microbiology culture results for percutaneous endoscopic gastrostomy tube conditioned saline 
(PEG-s) samples obtained from people with CF. 
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or Ranitidine, with an RSI score > 12; median RSI score 17 (range 13–36). One patient was EOR non symptomatic 
with RSI score 8.
RSI scores for patients positive for MABSC were higher (median 22, range 17–36) compared to patient who 
were negative for MABSC (median 15, range 8–20), but this was not statistically significant (p = 0.22). The cough 
domain score of the RSI questionnaire in MABSC positive patients ranged from 2–5, with 5 the highest score 
possible.
Discussion
For the first time to our knowledge, we have shown that MABSC can be isolated from the gastric juice and PEG 
tubes of patients with CF in addition to sputum. Previous reports where gastric juice has been shown to be an 
advantageous sample for diagnosing Mycobacterium tuberculosis add plausibility to this main finding11,12. We 
also found that isolates were obtained from a gastric source with MABSC negative sputa. MABSC were therefore 
identified for the first time from a gastric sample in these patients, despite rigorous and extended previous sputum 
based surveillance in a tertiary laboratory, with a specialised interest in MABSC culture methodology16.
Over the last 2 decades, with the increasing survival of patients with CF, a number of pathogens including 
MABSC have become of emergent, international importance. Outbreaks of MABSC in non-CF patients have also 
been reported and, for example, soft tissue, bone and line infections have occurred following the use of contam-
inated surgical equipment17.
To our knowledge there is no directly proven animal-to-human or human-to-human transmission of MABSC. 
Cross-infection between patients with CF has been suggested however, through elegant, indirect studies combin-
ing whole genome sequencing and detailed epidemiology8. Recently, Ricketts et al.18, provided, a case description 
of suspected human-to-human transmission of M. kansasii, involving genetically identical organisms isolated 
from a husband and wife living in East London. NTM outbreaks have been described following the use of disin-
fected surgical equipment in patients, with the presumption that this might be due to inadequate cleaning, or be 
derived from the water supply used to perform the disinfection. The exact source of such MABSC outbreaks has 
not been precisely identified however19.
A breach of “barrier defence” protection against microorganisms is a described risk factor for M. tuberculosis 
(TB)20. The stomach is not considered a primary site of infection in these patients, but illustrates this potential 
niche for mycobacterium and gastric juice can be used for the detection of pulmonary tuberculosis diagnosis in 
children13. No data are available regarding the potential to culture MABSC from gastrostomy to our knowledge 
however. We have recently shown that gastric juice is an under recognised reservoir of microorganisms relevant 
to people with CF9. Our previous paper investigated the aerodigestive microbiome in people with CF using Next 
Generation Sequencing but did not study NTM. Our present paper is independent of the first study, using differ-
ent samples involving the specialised methodology necessary for NTM studies. In this study we investigated the 
presence of MABSC isolated from sputum, gastric juice and PEG tubes in our regional CF clinic PEG fed patients. 
The prevalence of MABSC in our combined samples from our PEG fed cohort was 43%; a high rate compared to 
our latest regional institution study of non-PEG-fed CF patients (16%)16, and another recent study (12%)21. This 
may be related to the severity of disease in our PEG-fed patients, however it may also be possible that the presence 
of a PEG may be associated with MABSC isolation in people with CF.
Our data indicated that MABSC was present in the gastric compartment and was cultured from both gastric 
juice and PEG tubes. These PEG tubes were removed from patients as part of their routine management and not 
because of any clinical suspicion of infection. Our findings are in keeping with the known resistance of MABSC 
organisms to divergent environments including high temperature and low pH22.
We are unaware of substantive previous data regarding MABSC culture in non-CF gastric juice. However, we 
have previously studied the microbiology of 14 gastric juice samples sampled at diagnostic gastroscopy of patients 
without known lung disease. Our experience showed that In 6 patients whose gastric juice had a pH of 4 or less, 
bacteria were not cultured. The remaining 8 patients, whose gastric pH was 5 to 8, all had cultures that grew a 
range of bacteria. These isolates did not include any MABSC or other mycobacteria however23,24. Our previous 
preliminary data may therefore suggest some specificity to our finding of MABSC in gastric juice in our PEG fed 
CF patient group and we conclude that this requires further study. Such studies could explore a novel possibility; 
that the stomach constitutes a potential reservoir and niche of viable MABSC in PEG fed people with CF. We 
speculate that this may have a role in failure of eradication treatment in some patients.
Gastric juice sputum PEG NTM status
CF-1 M massiliense No MABSC isolated No PEG* no previous MABSC
CF-3 M massiliense M massiliense No PEG + ve for M massiliense since 6-12-06
CF-4 No MABSC isolated M abscessus sub sp abscessus M abscessus sub sp abscessus + ve for M abscessus 10-7-08
CF-6 No MABSC isolated M abscessus sub sp abscessus No MABSC isolated + ve for M abscessus 9-1-09
CF-9 No MABSC isolated M massiliense No PEG no previous MABSC
CF-13 M massiliense M massiliense No PEG Grew M chelonae once only
CF-14 No MABSC isolated No MABSC isolated
M abscessus sub sp 
abscessus Mycobacterium 
bolletii
no previous MABSC
Table 2.  Patient details related to chronic colonisation of NTM. Key: * = No PEG tube isolated from the 
patients.
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Our present study showed an association between MABSC colonisation of gastric juice and sputum in some of 
our CF patients. Two patients had MABSC in their gastric juice and sputum samples and where MABSC was found 
concordantly in CF gastric juice and sputum, we demonstrated genetically identical strains by molecular techniques.
Transfer of organisms including MABSC may be possible from lung to stomach through the widely recognised 
mechanism of cough and swallowing of expectorate. The finding of identical strains of P. aeruginosa cultured 
from the gastric juices and sputa further support the idea that sputum is being swallowed into the stomach. We 
also found that in a minority of the patients MABSC were isolated from the PEG and gastric juice of patients 
with MABSC negative sputa. A gastric sample therefore represented the first time that MABSC had been isolated 
in two patients from our series. These individuals also had negative sputum samples according to the routine 
clinical microbiology approaches in our centre in the year prior to the GI isolates. Our study cannot indicate that 
the stomach may be a primary site of infection with MABSC rather than just reflecting swallowing of infected 
sputum, but this could be a useful area of future research. We have also found that gastric juice and PEG tubes can 
be culture positive for P. aeruginosa, with no P. aeruginosa present in the earlier sputum samples. Future studies 
could therefore test the hypothesis that clinically relevant bacteria including MABSC survive in the gastric com-
partment independent from respiratory sources, which may have translational importance for the management 
of people with CF and approaches to attempted eradication of micro-organisms.
An association between NTM lung disease and gastroesophageal disorders has been suggested in previous 
reports including disease related to M abscessus25 and reflux and aspiration events have been widely documented 
in CF patients26. Our present study showed a high level of symptoms associated with reflux leaving the oesoph-
agus in our patient cohort, including cough. The validated RSI questionnaire instrument used in this study con-
sists of a series of 9 questions to evaluate extra-oesophageal reflux. All the patients in our cohort colonised with 
MABSC in their gastric compartment had a high RSI domain score for cough. A single cough can produce a large 
amount of bioaerosols, which may contribute to infectious disease transmission27.
It may therefore be relevant that non-CF patients with pulmonary Mycobacterium avium complex (MAC) 
have a higher incidence of GORD than is reported in the general population25,28. Moreover, it has been found that 
the use of regular acid-suppressive medication is associated with an increased risk of MAC pulmonary disease. 
Acid-suppressive medication is frequently used by CF patients and we have recently contributed to an active 
debate that PPI usage and raised gastric pH may be associated with bacterial growth23. A recent recommendation 
for management of NTM highlighted the potential importance of PPI as a risk factor2. We feel our data is con-
sistent with the need for further research to evaluate the potential roles of GORD and acid suppression, in studies 
of NTM in CF. A longitudinal study would be needed to address a potential risk of transfer of organisms to the 
lung from the stomach through mechanisms including cough and recurrent reflux and aspiration. We feel that 
this should be considered and investigated in CF, and it would be important to also consider the lifelong use of 
antibiotics in CF patients and their overall effect on microbiomes.
Gastrostomy tube placement is a well-established and tolerated method to augment feeding in patients with 
CF. The gastrostomy tube may be placed endoscopically, surgically, or fluoroscopically. Foreign body-associated 
MABSC infections are increasingly recognised now receiving increasing emphasis because of the increased use 
of indwelling medical devices29. The presence of a foreign body is believed to facilitate colonisation by weakening 
host barrier defence mechanisms30. An individual case of perigastrostomy infection caused by M abscessus in an 
immunocompetent patient has been reported31.
Because MABSC are resistant to conventional antibiotics and anti-tuberculosis drugs, it is important to rec-
ognize this specific group of pathogens, particularly in patients with CF. Early identification may allow timely 
susceptibility testing, appropriate therapy and PEG management. A strength of our study therefore is that to our 
knowledge, our findings are the first data showing gastric juice and PEG-tube insertion are a potential niche for 
MABSC in patients with CF. A weakness of our study is that alongside previous influential studies on MABSC in 
CF our cohort size was modest and our study is cross sectional. The presence of the PEG allows access to gastric 
juice without potential commensal sampling from the upper airways but this means that our findings are limited 
to PEG fed patients with CF. We feel that our preliminary findings might usefully be followed up longitudinally 
in multi-centre approaches, in a wider range of patients. With clinical concerns raised about the increasing prev-
alence of MABSC in CF we conclude that such studies are warranted.
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